Malaysian Genomics and Rinani Genotec sign letter of intent with Universiti Malaysia Sabah


The parties agree to collaborate on research in genetics, regenerative and alternative medicine

PETALING JAYA, Malaysia – Leading specialist in genomics and biopharmaceuticals Malaysian Center for Genomic Resources Berhad (Sotck exchange: MGRC, 0155) is pleased to announce that the Group has signed a Letter of Intent (LOI) with the Faculty of Science and Natural Resources, Universiti Malaysia Sabah (UMS) and Rinani Genotec Sdn Bhd (Genotec) to collaborate on research and development (R&D) in genetics and regenerative and alternative medicine.

As part of the LOI, the MGRC, which has a high-throughput sequencing lab, a state-of-the-art microarray facility and a new state-of-the-art cell processing lab, as well as Genotec, which specializes in biomedical treatments using stem cells, will help strengthen the teaching and research activities of the undergraduate program of the Faculty of Science and Natural Resources of UMS.

This cooperation will allow the exchange of resources and research ideas to improve the quality of research at UMS, as well as create opportunities for students of the Faculty of Science and Natural Resources to do their internship at the MGRC or at Genotec.

President of Malaysian Genomics, Datuk Seri Dr. Chen Chaw Minsaid: “We are pleased to support UMS undergraduate students in pursuing their R&D goals so that they have a better understanding of their field of study. This is also in support of the policy national biotechnology 2.0 launched recently focusing on agriculture and food security, healthcare and well-being, as well as circular industry and academia.

The signing of the Letter of Intent follows UMS’s visit to the MGRC’s Biosafety Level 2 cGMP (Current Good Manufacturing Practice) certified laboratory, which is used for the production of cell therapies, including cell therapies CAR T for various cancers.

Malaysian Center for Genomic Resources Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK],


(C) 2022 M2 COMMUNICATIONS, source M2 PressWIRE


Comments are closed.